Ratings for Stryker (NYSE:SYK) were provided by 14 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 7 | 2 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 1 | 0 | 0 |
| 3M Ago | 4 | 6 | 1 | 0 | 0 |
Analysts have set 12-month price targets for Stryker, revealing an average target of $378.57, a high estimate of $405.00, and a low estimate of $351.00. This current average has increased by 5.25% from the previous average price target of $359.67.
Exploring Analyst Ratings: An In-Depth Overview
In examining recent analyst actions, we gain insights into how financial experts perceive Stryker. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Vijay Kumar | Evercore ISI Group | Lowers | Outperform | $365.00 | $370.00 |
| David Roman | Goldman Sachs | Announces | Neutral | $372.00 | - |
| Mike Matson | Needham | Announces | Buy | $392.00 | - |
| Matt Miksic | Barclays | Raises | Overweight | $376.00 | $372.00 |
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $381.00 | $364.00 |
| Jason Wittes | Roth MKM | Raises | Buy | $405.00 | $348.00 |
| Danielle Antalffy | UBS | Raises | Neutral | $351.00 | $339.00 |
| Matt O'Brien | Piper Sandler | Raises | Overweight | $380.00 | $375.00 |
| Rick Wise | Stifel | Raises | Buy | $375.00 | $350.00 |
| Ryan Zimmerman | BTIG | Raises | Buy | $369.00 | $366.00 |
| Jeff Johnson | Baird | Raises | Outperform | $378.00 | $367.00 |
| Shagun Singh | RBC Capital | Raises | Outperform | $386.00 | $360.00 |
| Joshua Jennings | TD Cowen | Raises | Buy | $400.00 | $365.00 |
| Vijay Kumar | Evercore ISI Group | Raises | Outperform | $370.00 | $340.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Stryker. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Stryker compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Stryker's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
To gain a panoramic view of Stryker's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Stryker analyst ratings.
Delving into Stryker's Background
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and spinal devices. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.
Stryker's Economic Impact: An Analysis
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Stryker displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 9.73%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Stryker's net margin excels beyond industry benchmarks, reaching 15.03%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Stryker's ROE stands out, surpassing industry averages. With an impressive ROE of 4.17%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Stryker's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.99%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.67.
How Are Analyst Ratings Determined?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.